<span item_type="fundamental" item_id="f4ade2a32426a915ff6318c4aea2b0e7" counter_id="ST/US/GRCE" env="prod"></span><span item_type="announcement" item_id="548595126185627905" env="prod"></span><p>EPS: As of FY2026 Q1, the actual value is USD -0.21.</p><p></p><h3>Financial Results for First Quarter 2026</h3><h4>Net Loss</h4><ul><li>The company reported a net loss of $3.4 million, or $0.21 per share, for the three months ended June 30, 2025, compared to a net loss of $2.6 million, or $0.24 per share, for the same period in 2024. The increase in net loss was primarily due to a $1.9 million change in the fair value of derivative warrant liabilities and a $0.7 million decrease in income tax benefit, partially offset by a $1.8 million decrease in research and development expenses and a $0.1 million decrease in general and administrative expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_ex99-1.htm"></span></li></ul><h4>Research and Development Expenses</h4><ul><li>Total research and development expenses were approximately $0.9 million for the three months ended June 30, 2025, compared to $2.7 million for the same period in 2024. The decrease of approximately $1.8 million was primarily due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety clinical trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_ex99-1.htm"></span></li></ul><h4>General and Administrative Expenses</h4><ul><li>General and administrative expenses were approximately $2.1 million for the three months ended June 30, 2025, a decrease of $0.1 million from $2.2 million for the same period in 2024. This decrease was mainly due to reduced legal, accounting, tax, audit, and other professional fees, offset by increased salaries and benefits, and costs for GTx-104 commercial assessment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_ex99-1.htm"></span></li></ul><h4>Cash and Cash Equivalents</h4><ul><li>As of June 30, 2025, cash and cash equivalents were $20.0 million, a net decrease of approximately $2.1 million from $22.1 million at March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_ex99-1.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>Grace Therapeutics anticipates that its current cash and cash equivalents will provide a cash runway through at least the next twelve months, potentially extending into the second quarter of 2027 if all common warrants from the February 2025 and September 2023 private placements are exercised.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_ex99-1.htm"></span></li></ul>

Grace Therapeutics | 8-K: FY2026 Q1 EPS: USD -0.21